Avenue Therapeutics (ATXI) Short Interest Ratio & Short Volume → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free ATXI Stock Alerts $3.73 +0.10 (+2.75%) (As of 05/17/2024 08:53 PM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaSustainability Avenue Therapeutics Short Interest DataCurrent Short Volume17,100 sharesPrevious Short Volume193,600 sharesChange Vs. Previous Month-91.17%Dollar Volume Sold Short$85,671.00Short Interest Ratio / Days to Cover0.3Last Record DateApril 30, 2024Outstanding Shares590,000 sharesFloat Size525,000 sharesShort Percent of Float3.26%Today's Trading Volume38,900 sharesAverage Trading Volume80,199 sharesToday's Volume Vs. Average49% Short Selling Avenue Therapeutics ? Sign up to receive the latest short interest report for Avenue Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatATXI Short Interest Over TimeATXI Days to Cover Over TimeATXI Percentage of Float Shorted Over Time Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry Avenue Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/202417,100 shares $85,671.00 -91.2%3.3%0.3 $5.01 4/15/2024193,600 shares $24,200.00 -31.6%N/A0.1 $0.13 3/31/2024283,100 shares $41,757.25 -9.7%N/A0.1 $0.15 3/15/2024313,400 shares $49,360.50 +91.7%N/A0.1 $0.16 2/29/2024163,500 shares $24,802.95 -51.6%N/A0 $0.15 2/15/2024337,700 shares $49,743.21 -50.1%N/A0.1 $0.15 Get the Latest News and Ratings for ATXI and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Avenue Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/2024677,300 shares $100,240.40 -39.0%N/A0.1 $0.15 1/15/20241,110,000 shares $193,140.00 +378.9%N/A0.2 $0.17 12/31/2023231,800 shares $37,319.80 +1.2%3.1%0 $0.16 12/15/2023229,100 shares $33,906.80 -65.6%2.4%0.1 $0.15 11/30/2023665,300 shares $141,043.60 +329.8%9.2%0.4 $0.21 11/15/2023154,800 shares $28,730.88 -69.9%1.6%0.8 $0.19 10/31/2023513,700 shares $120,719.50 +39.0%7.7%3.3 $0.24 10/15/2023369,700 shares $221,746.06 +73.2%5.6%5.7 $0.60 9/30/2023213,400 shares $150,873.80 +699.3%3.3%2.9 $0.71 9/15/202326,700 shares $22,134.30 +184.0%0.5%0.4 $0.83 8/31/20239,400 shares $7,294.40 -69.9%0.1%0.2 $0.78 8/15/202331,200 shares $31,200.00 -47.7%0.5%0.5 $1.00 7/31/202359,600 shares $62,580.00 -12.2%0.9%0.8 $1.05 7/15/202367,900 shares $81,276.30 -45.9%1.1%0.7 $1.20 6/30/2023125,400 shares $144,210.00 -4.7%2.0%0.6 $1.15 6/15/2023131,600 shares $152,656.00 -32.7%2.1%0.5 $1.16 5/31/2023195,500 shares $211,140.00 -35.0%3.3%0.5 $1.08 5/15/2023300,700 shares $321,749.00 -16.3%5.1%0.6 $1.07 4/30/2023359,100 shares $341,109.09 +49.8%5.2%0.7 $0.95 4/15/2023239,700 shares $261,273.00 -16.6%3.9%0.4 $1.09 3/31/2023287,300 shares $334,704.50 -36.7%4.8%0.3 $1.17 3/15/2023453,900 shares $531,063.00 +208.8%7.5%0.5 $1.17 2/28/2023147,000 shares $163,170.00 -10.7%2.4%0.2 $1.11 2/15/2023164,600 shares $204,104.00 -42.8%2.7%0.2 $1.24 1/31/2023287,500 shares $396,750.00 +229.0%6.6%0.3 $1.38 1/15/202387,400 shares $106,628.00 -16.4%2.1%0.1 $1.22 12/30/2022104,500 shares $121,220.00 -17.1%2.4%0 $1.16 12/15/2022126,100 shares $156,364.00 -8.5%2.8%0 $1.24 11/30/2022137,800 shares $184,652.00 +66.2%3.1%0 $1.34 11/15/202282,900 shares $137,614.00 -61.0%1.9%0 $1.66 10/31/2022212,600 shares $508,114.00 +1,463.2%5.6%0.1 $2.39 10/15/202213,600 shares $45,288.00 -97.4%0.4%0 $3.33 9/30/2022524,700 shares $5.29 million +1,836.2%69.5%0.2 $10.08 9/15/202227,100 shares $108,535.50 -82.1%N/A0.1 $4.01This Apple-like Innovator is Revolutionizing Healthcare (Ad)AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry ATXI Short Interest - Frequently Asked Questions What is Avenue Therapeutics' current short interest? Short interest is the volume of Avenue Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, investors have sold 17,100 shares of ATXI short. 3.26% of Avenue Therapeutics' shares are currently sold short. Learn More on Avenue Therapeutics' current short interest. What is a good short interest percentage for Avenue Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 3.26% of Avenue Therapeutics' floating shares are currently sold short. Is Avenue Therapeutics' short interest increasing or decreasing? Avenue Therapeutics saw a decline in short interest in the month of April. As of April 30th, there was short interest totaling 17,100 shares, a decline of 91.2% from the previous total of 193,600 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Avenue Therapeutics' float size? Avenue Therapeutics currently has issued a total of 589,000 shares. Some of Avenue Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Avenue Therapeutics currently has a public float of 525,000 shares. How does Avenue Therapeutics' short interest compare to its competitors? 3.26% of Avenue Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Avenue Therapeutics: Altamira Therapeutics Ltd. (6.57%), Dermata Therapeutics, Inc. (1.28%), Salarius Pharmaceuticals, Inc. (1.65%), Clearmind Medicine Inc. (5.51%), CNS Pharmaceuticals, Inc. (0.31%), Sonoma Pharmaceuticals, Inc. (0.30%), Notable Labs, Ltd. (0.08%), Onconetix, Inc. (0.31%), Galmed Pharmaceuticals Ltd. (1.49%), 60 Degrees Pharmaceuticals, Inc. (1.31%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Avenue Therapeutics stock? Short selling ATXI is an investing strategy that aims to generate trading profit from Avenue Therapeutics as its price is falling. ATXI shares are trading up $0.10 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Avenue Therapeutics? A short squeeze for Avenue Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ATXI, which in turn drives the price of the stock up even further. How often is Avenue Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ATXI, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: CYTO Short Squeeze DRMA Short Squeeze SLRX Short Squeeze CMND Short Squeeze CNSP Short Squeeze SNOA Short Squeeze NTBL Short Squeeze ONCO Short Squeeze GLMD Short Squeeze SXTP Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ATXI) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldDoes this make you sick?Allegiance GoldUrgent Nvidia WarningAltimetryThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarShocking: One AI startup's revenue could surge 4,735%Manward PressGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders